Stay updated with breaking news from Vabysmo Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema ... | April 25, 2023
Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) - More
29.01.2022 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration ... Seite 1